AHArash Haghikia

Arash Haghikia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Arash Haghikia has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Denise Hilfiker-Kleiner

    Department of Cardiology and Angiology, Medical School Hannover, Hannover, Germany

    3 shared publications
  • Dominik Berliner

    Department of Cardiology and Angiology, Medical School Hannover, Hannover, Germany

    3 shared publications
  • Johann Bauersachs

    Department of Cardiology and Angiology, Hannover Medial School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany

    3 shared publications
  • Denise Hilfiker-Kleiner

    Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany

    2 shared publications
  • Dieter Fischer

    Department of Cardiology and Angiology, University Hospital Muenster, Muenster, Germany

    2 shared publications
  • Edith Podewski

    Department of Cardiology and Angiology Hannover Medical School Hannover Germany

    2 shared publications

Latest Publications

  • Early ivabradine treatment in patients with acute peripartum cardiomyopathy: Subanalysis of the German PPCM registry

    by Arash Haghikia, Jörn Tongers, Dominik Berliner, Tobias König, Andreas Schäfer, Michael Brehm, Michael Böhm, Denise Hilfiker-Kleiner, Johann Bauersachs


  • Evidence of autoantibodies against cardiac troponin I and sarcomeric myosin in peripartum cardiomyopathy

    by Arash Haghikia, Ziya Kaya, Johannes Schwab, Ralf Westenfeld, Philipp Ehlermann, Katrin Bachelier, Renate Oettl, Constantin S. von Kaisenberg, Hugo A. Katus, Johann Bauersachs, et al.

    Peripartum cardiomyopathy (PPCM) is a major cause of pregnancy-related maternal heart failure that develops towards the end of pregnancy or in the months following delivery. In small retrospective case series, autoimmune responses in the pathogenesis of PPCM have been proposed upon identification of autoantibodies (AABs) to cardiac antigens. However, their clinical and prognostic relevance still remain unclear. In this study, we evaluated the presence of circulating AABs against cardiac sarcomeric myosin (MHC) and troponin I (TnI) in the sera of PPCM patients and in relation to clinical presentation. In this case–control study, 70 patients diagnosed with PPCM and 50 pregnancy-matched healthy women with normal cardiac function were enrolled. Clinical assessment, echocardiography and blood tests were performed at baseline and at 6 ± 2 months follow-up. The presence of serum AABs against MHC (anti-MHC) and TnI (anti-TnI) was determined with a custom-made enzyme-linked immunosorbent assay (ELISA). The seropositivity for these AABs was correlated with the severity of LV dysfunction and the occurrence of pericardial effusion indicative of perimyocardial inflammation at baseline. Potential impact of these AABs on disease progression was evaluated with regard to functional (left ventricular ejection fraction) and clinical improvement at follow-up. Either anti-MHC or anti-TnI or both AABs were detected in the serum of 46 % of PPCM patients and in 8 % of healthy controls. In PPCM the presence of either one of these AABs was associated with significantly lower baseline LVEF and lower rate of full cardiac recovery at follow-up. Patients who were seropositive for anti-TnI AABs showed more frequently pericardial effusion indicative of a more pronounced immune response of the peri-/myocardium in these patients. Further studies are required to clarify cellular and molecular circuits leading to elevated levels of AABs and their pathophysiological relevance for disease initiation and progression in PPCM.


  • Open Access

    Prognostic Implication of Right Ventricular Involvement in Peripartum Cardiomyopathy: A Cardiovascular Magnetic Resonance Study

    by Arash Haghikia, Philipp Röntgen, Jens Vogel-Claussen, Johannes Schwab, Ralf Westenfeld, Philipp Ehlermann, Dominik Berliner, Edith Podewski, Denise Hilfiker-Kleiner, Johann Bauersachs

    Aims Peripartum cardiomyopathy (PPCM) is a major cause of acute heart failure in the peripartum period and considered potentially life threatening. While many aspects of its clinical profiles have been frequently reported, functional analysis, in particular of the right ventricle, and tissue characterization by cardiovascular magnetic resonance (CMR) imaging have been only sporadically described. The aim of the present study was to analyse pathological alterations and their prognostic relevance found in CMR imaging of patients newly diagnosed with PPCM. Methods and results In this multicenter study 34 patients with confirmed PPCM underwent CMR imaging at the time of diagnosis and at 5 ± 1 months follow-up. Cine imaging of PPCM patients showed moderate to severe reduction of systolic left ventricular (LV) function (mean LVEF: 29.7 ± 12.8%). In 35% of the patients right ventricular (RV) systolic function was also reduced with a mean RVEF of 42.9 ± 13.9%. Dilatation of the LV was observed in 91% (mean LV-EDV/BSA 128.5 ± 32.1 mL/m2), and dilatation of the RV was present in 24% (mean RV-EDV/BSA 87.4 ± 18.5 mL/m2) of the patients. Focal non-ischemic late gadolinium enhancement (LGE) was visible in 71%, and regional wall motion abnormalities were evident in 88% of the patients. LGE and wall motion abnormalities were predominantly located in the anteroseptal and basal to midventricular segments. RV dysfunction at baseline was associated with reduced probability of full cardiac recovery at 5 ± 1 months follow-up. Conclusions Besides LV systolic dysfunction, RV dysfunction and dilatation are observed in about one third of PPCM patients at the time of diagnosis. RV dysfunction is associated with unfavourable outcome. A distinct pattern of LV wall motion abnormalities and myocardial scar is evident in most PPCM patients. The present study may help to establish a set of CMR criteria suitable for diagnosis in patients with suspected PPCM and may add further knowledge to the pathology of the disease.


  • Open Access

    Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy

    by Arash Haghikia, Edith Podewski, Dominik Berliner, Kristina Sonnenschein, Dieter Fischer, Christiane E. Angermann, Michael Böhm, Philipp Röntgen, Johann Bauersachs, Denise Hilfiker-Kleiner

    Background Peripartum cardiomyopathy (PPCM) is an idiopathic heart disease that develops in the last month of pregnancy and/or the first months following delivery in previously healthy women and may lead to acute heart failure. A cleaved fragment of the nursing hormone prolactin is considered essential in the pathophysiology of PPCM. To date, no specific therapy has been tested for PPCM in a randomized controlled trial of adequate size. Aims The purpose of this trial is to investigate the safety of the dopamin-D2-receptor agonist bromocriptine and its effects on left ventricular (LV) function in women with PPCM. Methods This is an 11 center German trial with a prospective randomized controlled open-label design. The trial enrolls females with newly diagnosed PPCM according to European Society of Cardiology criteria with a LV ejection fraction (LVEF) <35 %. Patients are randomized 1:1 to either best supportive care (BSC) including standard heart failure therapy plus 8 weeks of bromocriptine therapy (2.5 mg b.i.d. for 14 days and 2.5 mg q.d. from day 15 to 56) or to BSC plus 1 week of low-dose bromocriptine (2.5 mg q.d.) with anticoagulant therapy at a prophylactic dose administered during the period of bromocriptine treatment in both groups. The primary endpoint is change in LVEF from baseline to 6 months follow-up as assessed by cardiac magnetic resonance imaging (or echocardiography if CMR is not tolerated). The secondary endpoints are hospitalization for worsening heart failure, heart transplantation, and all-cause mortality during follow-up or a combination of these endpoints. A total of 60 patients will be recruited (including 6 potential dropouts) giving a power of 0.9 for an expected LVEF change of 10.8 % between treatment groups at 6 months. Perspective This trial will provide important knowledge on potential benefits and safety of prolonged inhibition of prolactin release with bromocriptine in addition to standard heart failure therapy in newly diagnosed PPCM. Trial registration: ClinicalTrials.gov Identifier: NCT00998556.


  • Open Access

    Progressive multifocal cerebral infarction in a young kidney transplant recipient due to thrombotic microangiopathy

    by Arash Haghikia, Meike Heeren, Clemens Bockmeyer, Bernd Haubitz, Wilfried Gwinner

    Renal transplant recipients frequently experience neurological complications. Whereas ischemic stroke, cerebral haemorrhage or hypertensive encephalopathy often result from vascular alterations prior to transplantation, other cerebral diseases like CNS infections, primary brain tumors and drug induced neurotoxicity may develop as consequences of the required post-transplant immunosuppressive treatment.


  • Organ transplants do not escape paradoxical embolisms

    by Arash Haghikia, Marcus Hiss, Kristina Imeen Ringe, Eva Schoenenberger, Dieter Fischer, Hermann Haller, Wilfried Gwinner

    Acute renal allograft dysfunction in the first weeks after transplantation primarily requires examination for acute rejection, drug-associated injury, pre-renal failure due to exsiccosis/dehydration, and post-renal problems such as urinary tract obstruction. In rare instances, main renal artery or vein thrombosis may be found, e.g. due to acute rejection of the vessels. Herein, we describe the clinical course of a patient with a recent renal transplantation who presented with an acute enigmatic renal allograft failure which, after intensive diagnostic efforts, emerged as paradoxical embolism with extensive allograft ischemia in consequence of a venous thrombosis and a patent foramen ovale - a so far unreported case.


  • Peripartum Cardiomyopathy: Role of STAT-3 and Reactive Oxygen Species

    by Denise Hilfiker-Kleiner, Arash Haghikia, Andres Hilfiker